Advertisement
Screener

NewAmsterdam Pharma Company N.V. (NAMS) Net Margin

NewAmsterdam Pharma Company N.V. (NAMS) Net Margin

  • 2026-06-30: Net Margin -1732.91%.
  • 2026-03-31: Net Margin -1593.45%.
  • 2025-12-31: Net Margin -234134.38%.
  • 2025-09-30: Net Margin -20691.09%.

Complete source-backed net margin history.

Available history
2022-12-31 to 2026-06-30
Data captured

Historical Net Margin

DateNet Margin
2026-06-30-1732.91%
2026-03-31-1593.45%
2025-12-31-234134.38%
2025-09-30-20691.09%
2025-06-30-90.70%
2025-03-31-1327.30%
2024-12-31-721.71%
2024-09-30-57.18%
2024-06-30-1711.58%
2024-03-31-6692.86%
2023-12-31-6163.76%
2023-09-30-1602.62%
2023-06-30-2230.11%
2023-03-31-486.94%

Annual Net Margin

DateNet Margin
2025-12-31-905.74%
2024-12-31-530.25%
2023-12-31-1255.76%
2022-12-31-22.04%

Similar stocks

Stock NameCountryMarket CapPE Ratio
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67